Xspray Pharma Q2 2025: Case defining months ahead - Redeye

Redeye provides an update on Xspray following its Q2 report. The company faces two near-term material events: the NDA submission of its nilotinib candidate, XS003, and the PDUFA date for its lead candidate, Dasynoc, in October, offering opportunities for near-term share price-supportive newsflow.

Länk till analysen i sin helhet: https://www.redeye.se/research/1122668/xspray-pharma-q2-2025-case-defining-months-ahead?utm_source=finwire&utm_medium=RSS